- Home
- KALV vs CABO Comparison
KALV vs CABO Comparison
Compare KALV & CABO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- CABO
- Stock Information
- Founded
- KALV N/A
- CABO 1980
- Country
- KALV United States
- CABO United States
- Employees
- KALV N/A
- CABO N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- CABO Cable & Other Pay Television Services
- Sector
- KALV Health Care
- CABO Telecommunications
- Exchange
- KALV Nasdaq
- CABO Nasdaq
- Market Cap
- KALV 796.4M
- CABO 748.3M
- IPO Year
- KALV N/A
- CABO N/A
- Fundamental
- Price
- KALV $10.95
- CABO $174.77
- Analyst Decision
- KALV Strong Buy
- CABO Hold
- Analyst Count
- KALV 8
- CABO 3
- Target Price
- KALV $26.43
- CABO $171.00
- AVG Volume (30 Days)
- KALV 1.5M
- CABO 112.2K
- Earning Date
- KALV 09-11-2025
- CABO 11-06-2025
- Dividend Yield
- KALV N/A
- CABO 3.36%
- EPS Growth
- KALV N/A
- CABO N/A
- EPS
- KALV N/A
- CABO N/A
- Revenue
- KALV $1,426,000.00
- CABO $1,542,441,000.00
- Revenue This Year
- KALV N/A
- CABO N/A
- Revenue Next Year
- KALV $213.43
- CABO N/A
- P/E Ratio
- KALV N/A
- CABO N/A
- Revenue Growth
- KALV N/A
- CABO N/A
- 52 Week Low
- KALV $7.30
- CABO $117.54
- 52 Week High
- KALV $17.28
- CABO $437.00
- Technical
- Relative Strength Index (RSI)
- KALV 27.85
- CABO 57.29
- Support Level
- KALV $11.93
- CABO $169.91
- Resistance Level
- KALV $12.43
- CABO $178.85
- Average True Range (ATR)
- KALV 0.60
- CABO 6.81
- MACD
- KALV -0.22
- CABO 0.23
- Stochastic Oscillator
- KALV 6.17
- CABO 81.15
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
About CABO Cable One Inc.
Cable One Inc. is a telecommunications company that generates revenue from providing broadband, voice, and video services to both residential and business customers. From a product standpoint, the majority of revenue comes from data and video services, which are subscription-based and billed monthly. The company also offers Sparklight TV, an Internet Protocol Television (IPTV) service that enables customers using the Sparklight TV app to stream video channels from the cloud. Additionally, the company earns advertising revenue by selling airtime on its video channels, and it provides voice services over Internet protocols. Cable One Inc. owns its telecommunications infrastructure.